The bone-derived hormone osteocalcin has become synonymous with the skeletal regulation of energy metabolism, in part because this was the first endocrine function ascribed to this hormone
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. Although energy metabolism is certainly a critical aspect of osteocalcin biology (whereby in mice 2 , rats and humans [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] , osteocalcin affects the functions of β-cells 13 , myoblasts and probably other cell types), it by no means tells the entire story of osteo calcin. A hallmark of this hormone is that it regulates a large and continually growing number of physiological functions and developmental processes 14 (FIG. 1) . This Review focuses exclusively on one aspect of osteocalcin biology -its regulation of brain development and function, which is sometimes overlooked. However, this function of osteo calcin is of fundamental importance to link this hormone to the biology of ageing. The first reason to write a review on this topic at the present time is that the biomedical importance of the regulation of several behaviours by osteocalcin was underscored and linked to the ageing of the brain in a paper published in 2017 (REF. 15) . A second reason is that major progress has been made over the past few years in elucidating the molecular basis of the functions of osteocalcin in the brain 15 . These advances illustrate the growing reach of this hormone as well as the similarities and differences between the peripheral and central functions of osteocalcin.
The function of osteocalcin in the brain
Demonstrating that anxiety-like behaviour and cognition are affected by a molecule made in a peripheral organ has never been an easy or straightforward task. What led to this suspicion in the case of osteocalcin (which is encoded by Bglap, also known as Osteocalcin) was simply the fact that the extreme passivity of Osteocalcin -/-mice 16 could not be explained by any other means. What was already known about osteocalcin when we started to investigate this functionality was that when under carboxylated, this molecule promotes insulin secretion and glucose homeostasis in animals fed a normal diet 1, 13, 17 . Undercarboxylated osteocalcin also promotes testosterone synthesis in Leydig cells of the testis but not in follicular cells of the ovary because its receptor is expressed in the male but not in the female gonads [18] [19] [20] [21] . Although low circulating levels of testosterone affect several behaviours in male mice 22, 23 , a poorly defined yet evident passivity was observed in both male and female Osteocalcin -/-mice. Hence, this finding excluded the possibility that this phenotype was due to a defect in sex steroid hormone synthesis, as this process is not affected by osteocalcin in female mice 18 . Likewise, it became clear that the passivity of Osteocalcin -/-mice was not secondary to their abnormal glucose metabolism, as this passivity was not seen in Osteocalcin in the brain: from embryonic development to age-related decline in cognition Abstract | A remarkable, unexpected aspect of the bone-derived hormone osteocalcin is that it is necessary for both brain development and brain function in the mouse, as its absence results in a profound deficit in spatial learning and memory and an exacerbation of anxiety-like behaviour.
The regulation of cognitive function by osteocalcin, together with the fact that its circulating levels decrease in midlife compared with adolescence in all species tested, raised the prospect that osteocalcin might be an anti-geronic hormone that could prevent age-related cognitive decline. As presented in this Review, recent data indicate that this is indeed the case and that osteocalcin is necessary for the anti-geronic activity recently ascribed to the plasma of young wild-type mice. The diversity and amplitude of the functions of osteocalcin in the brain, during development and postnatally, had long called for the identification of its receptor in the brain, which was also recently achieved. This Review presents our current understanding of the biology of osteocalcin in the brain, highlighting the bony vertebrate specificity of the regulation of cognitive function and pointing toward where therapeutic opportunities might exist.
mice lacking Gprc6a, the receptor used by osteocalcin to increase insulin synthesis in pancreatic β-cells 13, [24] [25] [26] . The fact that Gprc6a -/-mice had none of the behavioural abnormalities, such as increased passivity, increased anxiety and impaired memory, further explained below, has been important throughout our investigation of osteocalcin for several reasons. It enabled us to uncover a decrease in muscle function during exercise caused by the absence of osteocalcin signalling through G proteincoupled receptor family C group 6 member A (GPRC6A) in myoblasts 2 and to distinguish this effect from the passivity caused by the absence of osteo calcin signalling through a different receptor present in the brain. At the onset of the study, the brain-specific receptor was not known. This lack of explanation for the abnormal passivity of Osteocalcin -/-mice led to the suspicion that the phenotypes of these mice might indicate that osteocalcin normally signals and functions in the brain. What added considerable credence to this notion is that osteocalcin had been shown in the original study of its central function to cross the blood-brain barrier, as peripheral delivery of uncarboxylated osteo calcin in Osteocalcin -/-mice resulted in an accumulation of osteocalcin in specific regions of the brain, mainly in the midbrain and brainstem 24 . By contrast, when delivered peripherally, carbo xylated osteocalcin crossed the blood-brain barrier far less efficiently than uncarboxylated osteocalcin 24 . This observation led us to a remarkable string of findings.
Regulation of anxiety and cognition
Moving from the entire animal to the molecular level, we observed that from a young age (3 months old), adult mice lacking Osteocalcin displayed a substantial increase in anxiety-like behaviour, including increased aversion to lit and open spaces and decreased exploratory activity, compared with wild-type littermates and had a major deficit in learning and memory 24 . In the Morris water maze test, Osteocalcin -/-mice were simply unable to learn the location of the platform and find it in a timely fashion 27 . This finding identifies osteocalcin as a peripheral hormone exerting one of the strongest influences on spatial learning and memory.
Anatomically Accordingly, in electrophysiological assays, osteocalcin increased the activation of the action potential frequency of neurons by almost twofold in the brainstem and locus coeruleus 24 . Two experiments led to the conclusion that all these described abnormalities reflect the absence of osteocalcin signalling in the brains of adult mice. The first experiment found that the delivery of uncarboxylated osteocalcin to the brain, through intracerebroventricular infusion and at a dose that does not result in any measurable leakage of osteocalcin in the general circulation, fully corrects anxiety-like behaviour and memory phenotypes, as well as gene expression abnormalities, in mice 24 . Second, an osteoblast-specific deletion of Osteocalcin performed in adult mice resulted in the same increased anxiety-like behaviour phenotype and memory defect, albeit in less severe forms than those observed in Osteocalcin -/-mice
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. Neurotransmitter levels and gene expression were also considerably affected in mice with a postnatal and osteoblast-specific deletion of Osteocalcin 24 . As expected, the only phenotype that could not be recapitulated in mice lacking osteocalcin only during postnatal stages was a developmental change, that is, their hypomorphic hippocampi 24 .
The role of maternal osteocalcin Two reasons that it was suspected that osteocalcin influenced the brain during embryonic development were the normal brain development observed in mice lacking Osteocalcin in only osteoblasts during adulthood and their more modest deficit in spatial learning and memory. As osteocalcin expression is not detected in the mouse embryo before embryonic day (E) 17.5 (REFS 37, 38) , this hypothesis implied that maternal osteocalcin might cross the placenta and the blood-brain barrier to execute this putative function.
This hypothesis turned out to be correct. Maternal undercarboxylated osteocalcin begins to cross the placenta between E14.5 and E15.5 (REF. 24), at a time
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• Undercarboxylated osteocalcin regulates anxiety and cognition in adult mice • Osteocalcin is necessary and sufficient to correct age-related decline in cognitive function in mice • Mouse maternal osteocalcin contributes to brain development and the acquisition of cognitive function in the fetus starting at embryonic day (E) 14.5 • Probable G protein-coupled receptor 158 (GPR158) regulates the role of osteocalcin in anxiety and cognition in the mouse brain when the development of brain structures, such as the hippo campus, is in full speed 39 (FIG. 3) . A complicated but efficient breeding strategy could establish unambiguously that almost all the undercarboxylated osteocalcin found in an embryo before E18.5 is of maternal origin. Moreover, we showed that maternally derived osteocalcin is needed to ensure the proper progression of fetal neurogenesis and prevent neuronal apoptosis 24 . Maternal undercarboxylated osteocalcin is also necessary for the establishment of spatial learning and memory in adult mice 24 . Indeed, delivering uncarboxylated osteocalcin or vehicle to Osteocalcin -/-mothers crossed with Osteocalcin -/-fathers throughout pregnancy and testing the behavioural performance of their progeny at 3 months of age showed that maternal osteocalcin contributes to a substantial extent, but does not completely explain, the deficit in spatial learning and memory that is observed in adult Osteocalcin -/-mice 24 .
What did we learn? Taken together, this series of observations revealed several important and novel notions about brain physiology and brain development. Moreover, given where osteocalcin is synthesized, when taken at face value, these observations also enrich bone physiology. If one looks at brain physiology, these findings show unambiguously that peripheral hormones, and certainly one made in bone, osteocalcin, exert a rather powerful influence on neuronal activity, gene expression, neurotransmitter synthesis and, ultimately, behaviour, including anxiety-like behaviour, spatial learning and memory. This notion is of fundamental importance, as too often we conceive and study functions of a given organ while omitting the fact that this organ receives many inputs from other organs, most of which are still unknown. Underscoring the potential medical influence of this work, two retrospective studies performed in human participants 40, 41 after the initial paper of Oury et al. 24 was published have suggested a correlation between decreased circulating levels of osteocalcin and poor cognitive performance in healthy middle-aged and aged individuals (40-78 years of age). We are fully aware that these studies, because of their retrospective nature, can be seen as only encouraging and that prospective studies are now needed. In terms of brain development and physiology, this work shows that one molecular underpinning of the so-called Barker effect 42, 43 (the maternal influence on neuro psychological functions of the offspring) might be a lack of maternal osteocalcin. This observation is important if we consider that the Barker effect also includes the maternal influence on energy metabolism in the offspring, as energy metabolism is one of the main physiological processes regulated by osteocalcin [44] [45] [46] [47] [48] . How does one place these data in a broader context of bony-vertebrate-specific biology? Two aspects of osteocalcin biology are particularly helpful in that respect. The first is that in pre-pubescent mice and in humans, circulating levels of undercarboxylated osteocalcin decrease steeply before 9 months of age in the mouse and before age 30 and age 45 years in women and men, respectively, without reverting to levels observed during puberty 2 . In other words, circulating levels of osteocalcin are high during life stages when most skills are being learnt. Importantly for our purpose, this feature is specific to osteocalcin, as circulating levels of other bone-specific hormones such as sclerostin 49 increase with age. A second feature of osteocalcin that is worth mentioning is that circulating levels of undercarboxylated osteocalcin surge during exercise, and exercise is known to improve cognitive function 2, [50] [51] [52] [53] [54] . These findings raise the following interconnected questions: could the decrease in cognitive function that occurs during ageing be due, at least in part, to the reduction in circulating levels of osteocalcin, and could osteocalcin be sufficient to correct age-related cognitive defects?
In addition to these biomedical questions, there is also a molecular question that needs to be answeredhow does osteocalcin signal in the brain? Indeed, the fact that Gprc6a is not expressed anywhere that osteocalcin signals in the brain and does not mediate osteocalcin signalling in the brain excludes the possibility that the central functions of osteocalcin are secondary, even in part, to the peripheral ones. Once this point was made, the task remained to understand how osteocalcin signals in the brain by identifying its receptor in the brain. This advance could serve several purposes of varying nature. One purpose is to achieve a better understanding of how extracellular cues coming from the periphery can affect brain development and function. A second purpose is, depending on the pattern of expression of this receptor, to possibly broaden the portfolio of the central functions of osteocalcin. A third purpose, dependent on the nature of this receptor and of its pattern of expression, could be to harness the biology of the signalling axis between osteocalcin and its receptor for therapeutic purposes. A schematic representation of the physiological functions regulated by undercarboxylated osteocalcin in peripheral organs is shown. In the pancreas, undercarboxylated osteocalcin increases β-cell proliferation and insulin secretion. In the testis, it increases testosterone production and prevents the apoptosis of Leydig cells. In the muscle, it increases IL-6 production and nutrient uptake and utilization for the production of ATP to promote adaptation to exercise.
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was to determine how useful these findings could be or could become from a medical point of view, especially in the ageing population. This possibility stems from the severe behavioural phenotype of the Osteocalcin -/-mice and from the following observations. For instance, with the progressive ageing of the general population [55] [56] [57] , new ways to prevent age-related cognitive decline and other age-related diseases affecting brain functions are urgently needed [58] [59] [60] [61] [62] . Moreover, it has been shown that for every function regulated by undercarboxylated osteocalcin, delivery of exogenous uncarboxylated osteocalcin can improve the age-related decline of these functions 2, 24 . One reason for this finding could be that circulating levels of undercarboxylated osteocalcin plummet beyond midlife in all species tested 2, 63, 64 . Finally, the aforementioned clinical studies 40, 41 , which suggested an association between circulating levels of undercarboxylated osteocalcin and cognitive performance, were another reason to ask whether osteocalcin could be sufficient to restore cognitive function in older mice. We have begun to address this question in animal models in several ways.
The first method used the assay popularized by Villeda et al. 65 , which was published in 2014, showing that repeated injections of plasma obtained from 3-month-old mice could improve cognitive function in older mice (16- month-old mice; FIG. 4a) . We need to add a precision here: we, as well as many other laboratories, are able to make mice live beyond 24 months of age in the confined environment of a modern animal facility, and 24 months of age could be used as a definition of ageing. After reproducing the results of Villeda et al., we showed that by contrast, injections of plasma from 3-month-old Osteocalcin -/-mice into 16-month-old wild-type mice did not improve cognitive function or anxiety-like behaviour, but improvements were seen with plasma from 3-month-old wild-type mice 15 (FIG. 4a) .
Many possible factors could explain these results, yet they established, on genetic grounds, that osteocalcin is necessary for the beneficial effect of plasma from young mice on several brain functions in older mice 15 . To rule out the possibility that this inability of plasma from young Osteocalcin -/-mice to improve the behavioural performance of older mice represented a developmental effect and to link osteocalcin itself to the beneficial effect of plasma from young wild-type mice, older mice were injected with plasma from young Osteocalcin -/-mice with the addition of recombinant uncarboxylated osteocalcin ('spiked plasma') 15 (FIG. 4a) . The fact that this spiked plasma could improve cognitive function and decrease anxiety-like behaviour in older wild-type mice to the same extent as plasma from young wild-type mice was a strong indication that osteocalcin was not only necessary but also sufficient to improve cognitive function and to hamper anxiety-like behaviour in adult mice. In a similar experiment, depleting every form of osteocalcin from the plasma of young wild-type mice through immunological means removed the ability of plasma from wildtype mice to improve cognitive function and to decrease anxiety-like behaviour 15 (FIG. 4b) .
Another experiment has provided the most direct evidence that osteocalcin is sufficient to rescue agerelated cognitive decline and to decrease anxiety-like behaviour and functions independent of any developmental effect. As osteocalcin crosses the blood-brain barrier 24 , we subcutaneously implanted mini osmotic pumps delivering uncarboxylated osteocalcin or vehicle in wild-type mice that were either 10 or 14 months old for 60 days 15 . The mice were analysed at 12 or 16 months old. Long-term delivery of uncarboxylated osteocalcin in mice aged 10 or 14 months fully rescued their deficit in cognitive function and decreased their anxiety-like behaviour 15 .
In exploring the molecular bases of this remarkable ability of osteocalcin to rescue age-related cognitive decline, several lines of experimental evidence pointed towards brain-derived neurotrophic factor (BDNF), a molecule well known to promote hippocampal-dependent Nature Reviews | Endocrinology , as a critical mediator of the regulation of cognitive function by osteocalcin. The first indication of this functionality was observed when monitoring multiple parameters of the transport of BDNF-containing dense-core vesicles in embryonic rat neurons in microchambers 70 . In this setting, uncarboxylated osteocalcin was able to stimulate the transport of BDNF-containing vesicles to synapses in rat neurons 15 . This translated to an increase in velocity and in the number of BDNF vesicles moving to the synapses. In in vitro studies, osteocalcin treatment of primary hippocampal neurons stimulated Bdnf expression. A second piece of evidence is supplied by in vivo studies showing that BDNF is a mediator of osteocalcin in the brain. Stereotaxic injection of uncarboxylated osteocalcin in the anterior hippocampi increased the accumulation of BDNF in the hippocampus. Lastly, peripheral injections of uncarboxylated osteocalcin increased Bdnf expression in the hippocampi of 16-month-old mice 15 . Similarly, injection of plasma from 3-month-old mice to 16-month-old mice increased BDNF accumulation in the hippocampi of 16-monthold mice 15 . This beneficial effect of young plasma on BDNF accumulation was abolished when plasma from 3-month-old Osteocalcin -/-mice was injected into 16-month-old wild-type mice 15 .
The receptor for osteocalcin in the brain The fact that osteocalcin was not only necessary but sufficient to improve cognitive decline at any age, though it is more effective in aged mice, and to reduce anxiety-like behaviour made it imperative to identify and characterize a receptor that mediates the functions of this hormone in the brain. To tackle this problem, three criteria were used to identify what could be a candidate receptor of osteocalcin in the brain. First, on the basis of what has been observed in many fields, we posited that a new receptor for osteocalcin should be a G protein-coupled receptor (GPCR) that belongs to the same class as GPRC6A, the class C family 71, 72 . This criterion, because the class C orphan GPCR list is rather small 73 , considerably reduced the number of options. A second criterion was that this orphan GPCR should be expressed in an area where it had been previously shown that osteo calcin binds. The third criterion was that this orphan GPCR should not be expressed in any of the cell types where GPRC6A mediates osteocalcin signalling 2, 13, 17, 18 . When these three criteria were used as a filter, only one orphan class C GPCR fulfilled all three: probable G protein-coupled receptor 158 (GPR158).
It remained then to demonstrate that GPR158 was the actual receptor of osteocalcin.
The pattern of expression for Gpr158 in the mouse brain was certainly consistent with this notion, as it is expressed in the CA3 region of the hippocampus, which is where osteocalcin binds; Gpr158 is expressed in pyramidal neurons and not in astrocytes in this area of the brain 15 . The fact that GPR158 was more abundant in hippocampi from Osteocalcin -/-mice than in those from wild-type mice was a further suggestion that it could be a receptor of osteocalcin in the hippocampus 15 . Like GPRC6A, GPR158 is expressed in humans in the same structures and regions as it is in the mouse 74, 75 . All the other data that support this hypothesis were of genetic nature and were obtained either via ex vivo or in vivo experiments 15 . For instance, local delivery of uncarboxylated osteocalcin in the anterior hippocampus induced protooncogene c-FOS accumulation, a marker of neuronal activity 76, 77 , in neurons of the CA3 region in wild-type mice but not in Gpr158 -/-mice 15 . Osteocalcin could bind a complex containing GPR158 and guanine nucleotidebinding protein α-q (Gαq, also known as GANQ) in solubilized membranes obtained from hippocampi from Osteocalcin -/-mice, whereas the quantity bound by osteocalcin was considerably reduced when using solubilized membranes obtained from hippocampi from Gpr158 -/-mice. In agreement with this observation, osteo calcin increased the accumulation of inositol triphosphate (IP 3 ), a second messenger used by GPCRs 78, 79 , in hippocampal neurons from wild-type but not Gpr158 -/-mice, where it consistently failed to increase cAMP accumulation. In whole-cell current clamp recording (an electrophysiological assay), osteocalcin increased the action potential frequency in pyramidal neurons of the CA3 region of the hippocampus of wild-type but not of Gpr158 -/-mice 15 ; this effect of osteocalcin was nearly abolished when using an IP 3 receptor antagonist (FIG. 5 ). An analysis of long-term potentiation 80, 81 verified that osteocalcin signals were in hippocampal slices from wild-type but not Gpr158 -/-mice 15 . Many genetic in vivo experiments also indicated that GPR158 is a receptor for osteocalcin in the brain 15 . For instance, whether we analysed mice lacking Gpr158 in only the forebrain or in all cells, we observed the same severe deficit in hippocampal-dependent memory 82 in mice lacking this receptor 15 . Likewise, Gpr158 -/-mice manifested more severe anxiety-like behaviour than wild-type littermates. That neither cognitive deficit nor Nature Reviews | Endocrinology Figure 4 | Osteocalcin is sufficient to improve cognition in aged mice. a | Injections of plasma from young (3 months) wild-type mice, which naturally contains undercarboxylated osteocalcin, into aged (16 months) wild-type mice improve memory and prevent anxiety-like behaviour. The improvement on memory and prevention of anxiety-like behaviour is not seen when plasma from young (3 months) Osteocalcin -/-mice is used instead of plasma from young wild-type mice. When Osteocalcin -/-plasma is spiked with mouse recombinant uncarboxylated osteocalcin, the ability of this plasma to improve cognitive functions is restored to the same extent as when using plasma from young wild-type mice 15 . b | Injection of control plasma from young mice (3 months) treated with an immunoglobulin G (IgG) antibody that does not recognize osteocalcin into aged (16 months) wild-type mice led to improved cognition. Injections of osteocalcin-depleted (by the use of an anti-osteocalcin IgG antibody) plasma from young (3 months) wild-type mice into aged (16 months) wild-type mice do not improve memory performance and do not prevent anxiety-like behaviour 15 anxiety-like behaviour could be corrected by chronic delivery of uncarboxylated osteocalcin in Gpr158 -/-mice established that GPR158 is necessary to mediate the regulation of cognitive function and anxiety-like behaviour by osteocalcin 15 . Two additional lines of evidence, of genetic nature, demonstrated that this is indeed the case. The first showed that stereotaxic injection of uncarboxylated osteocalcin in the anterior hippocampi improved hippocampal-dependent memory in wild-type mice but not in mice in which GPR158 accumulation had been decreased by a small hairpin RNA interference strategy 83 . Second, compound heterozygous mice lacking one allele of Gpr158 and one allele of Osteocalcin (Gpr158
) demonstrated the same cognitive deficits observed in Gpr158 -/-or in Osteocalcin -/-mice, whereas single heterozygous mice behaved like wild-type mice 15 . Independent of this body of work that identified GPR158 as a receptor mediating the regulation of cognitive function and anxiety-like behaviour by osteocalcin, several other important observations were made in the course of these investigations. One is that, as we had long surmised, osteocalcin function in the brain might not be limited to the hippocampus and the ventral tegmental area of the midbrain 24 . Indeed, a systematic analysis of Gpr158 expression showed that it is also expressed in the somatosensory area, the motor and auditory areas of the cortex, the piriform cortex and the retrosplenial area, where it was not known that osteocalcin binds 24 . A second more surprising observation that needs to be interpreted cautiously is that Gpr158 is not expressed in serotonergic neurons of the dorsal and medial raphe of the brainstem, where osteocalcin binds 15 . This observation suggests the possibility that a third receptor for osteocalcin exists.
Conclusions
What was illustrated through this work is a classic and fundamental principle of physiology; no organ, as noble as it might be, is an island that develops and functions at the exclusion of other organs. In our current era of biology, we have developed the tools to explore molecular events very effectively, and yet the study of mouse genetics has enabled us to uncover broader physiological phenomena that have remained hidden for a long time. What we did not know and could not have anticipated is that the skeleton, of all organs, would secrete a hormone that exerts such a powerful influence on the brain in the mouse and, it seems from retrospective studies, probably in humans as well.
Here, one should focus first and foremost on the salient features of osteocalcin and how they could help medicine. It is impossible to address these questions without considering the natural history of osteocalcin, whose circulating levels decrease around midlife in all species tested. This is a fundamental feature of osteocalcin in view of the fact that this hormone is necessary to maintain cognitive function at an optimal level and to decrease anxiety-like behaviour. Maybe more importantly from a medical point of view is the notion that osteocalcin is necessary and sufficient to correct age-related cognitive defects and to hamper anxiety-like behaviour. Together, these features identify osteocalcin as an antigeronic hormone that joins metalloproteinase inhibitor 2 (TIMP2) 84 on the list of anti-geronic molecules. The identification of a receptor for this hormone in the brain now raises the prospect that this interaction between osteocalcin and GPR158 could be used to treat various age-related degenerative conditions that affect the brain. This possibility might even be more important going forward, as the pattern of expression of Gpr158 suggests that we are not yet aware of all the functions of osteocalcin in the brain.
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The physiology and ageing of the brain are only one side of the coin. The other aspect one has to recognize is that osteocalcin is one of the first, if not the first, molecular substratum for the long-suspected maternal influence on brain development. How important the role of osteocalcin is in brain development is not yet fully known, in part because we do not know all the functions of osteocalcin in the brain and in part because we also do not know the pattern of expression of GPR158 in the developing brain. These notions and the possibility that a third receptor for osteocalcin might exist represent the most concrete challenges going forward. 
